First line chemotherapy with carboplatin plus paclitaxel in advanced ovarian cancer--a new standard of care?
about
Platelet effects on ovarian cancerPreclinical and clinical development of siRNA-based therapeuticsEffectiveness of carboplatin and paclitaxel as first- and second-line treatment in 61 patients with metastatic melanomaGenome wide DNA copy number analysis of serous type ovarian carcinomas identifies genetic markers predictive of clinical outcome.Anticancer activity of pristimerin in ovarian carcinoma cells is mediated through the inhibition of prosurvival Akt/NF-κB/mTOR signalingSecond-line chemotherapy for advanced or recurrent endometrial carcinoma previously treated with paclitaxel and carboplatin, with or without epirubicinFirst in-mouse development and application of a surgically relevant xenograft model of ovarian carcinoma.Anti-vascular therapies in ovarian cancer: moving beyond anti-VEGF approaches.The HDACi Panobinostat Shows Growth Inhibition Both In Vitro and in a Bioluminescent Orthotopic Surgical Xenograft Model of Ovarian Cancer.Update on first-line treatment of advanced ovarian carcinoma.A phase II feasibility study of carboplatin followed by sequential weekly paclitaxel and gemcitabine as first-line treatment for ovarian cancer.ROS mediate proapoptotic and antisurvival activity of oleanane triterpenoid CDDO-Me in ovarian cancer cellsSynthetic oleanane triterpenoid, CDDO-Me, induces apoptosis in ovarian cancer cells by inhibiting prosurvival AKT/NF-κB/mTOR signaling.S3-Guideline on Diagnostics, Therapy and Follow-up of Malignant Ovarian Tumours: Short version 1.0 - AWMF registration number: 032/035OL, June 2013.Molecular-targeted therapies for ovarian cancer: prospects for the future.Cyclin A1 expression and paclitaxel resistance in human ovarian cancer cells.Innovative strategy for treatment of lung cancer: targeted nanotechnology-based inhalation co-delivery of anticancer drugs and siRNA.Enhancement of antitumor activity of cisplatin in human lung cancer cells by tumor suppressor FUS1.Ifosfamide, paclitaxel and cisplatin first-line chemotherapy in advanced, suboptimally debulked epithelial ovarian cancer.A potentially neuroprotective role for erythropoietin with paclitaxel treatment in ovarian cancer patients: a prospective phase II GINECO trial.LAPTM4B overexpression is a novel predictor of epithelial ovarian carcinoma metastasis.BRCA mutations in the manifestation and treatment of ovarian cancer.Knockdown of FUSE binding protein 1 enhances the sensitivity of epithelial ovarian cancer cells to carboplatin.
P2860
Q26829401-D30091A8-9FF2-4335-9821-1F8B3F326C51Q28085290-66709FA9-9F7B-4617-B090-463D5502B6E6Q33831923-43387C6C-B1DF-4A72-9AA7-AA480CFB2A01Q34166257-75E93384-93C5-47C2-9582-BD3A380F9F23Q34719818-850D8748-6D3E-4A56-9773-E1F83AE4BE2EQ34724590-3DA28976-8B68-43EF-AFFF-20C2E6BDC750Q35110920-20808AA1-8458-42CB-B33F-509A7656BCBBQ35205410-340D8D67-0F71-4485-BF67-A36165DA3C39Q36063233-53A91CC6-0EDC-444E-87F9-3826B5CDCB80Q36571743-F6BF21DB-7679-4988-AA4D-AB30D8B4C450Q36626071-DDF1F2D0-11F0-49EA-816D-86B0C01A0A3BQ37011516-620516D1-3002-419C-80D5-EC4DE81D525BQ37011609-BE1BDD0A-F88E-4951-B52C-B8197002C572Q37383301-5BFA1829-0997-4D8E-A81C-94825EDC177FQ38036942-EADFC298-CD66-41CF-947D-88557FC7AE6DQ38743679-932707BA-5C3A-44BB-B187-3C01066F228AQ39461620-AB06BB1E-4403-43B2-AF6F-CE0A029BA3B1Q40082926-9E484D0A-A5F9-4DDD-9097-DFBACA62BE35Q43824337-76AF12B5-BB4D-4626-8EED-6011648C44FCQ44296616-022D70C3-7B0A-40C5-B416-F1BBA68A40F0Q45337300-01D24D95-3CA9-4C72-8AB4-185C51A4AA0CQ47134293-DAF0D35E-BE7D-4FD6-A66E-8427D6A32E09Q47158563-8D4C803E-056E-47A3-B52C-D1246B835D5C
P2860
First line chemotherapy with carboplatin plus paclitaxel in advanced ovarian cancer--a new standard of care?
description
1999 nî lūn-bûn
@nan
1999 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի հունվարին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
First line chemotherapy with c ...... ancer--a new standard of care?
@ast
First line chemotherapy with c ...... ancer--a new standard of care?
@en
type
label
First line chemotherapy with c ...... ancer--a new standard of care?
@ast
First line chemotherapy with c ...... ancer--a new standard of care?
@en
prefLabel
First line chemotherapy with c ...... ancer--a new standard of care?
@ast
First line chemotherapy with c ...... ancer--a new standard of care?
@en
P2093
P356
P1433
P1476
First line chemotherapy with c ...... ancer--a new standard of care?
@en
P2093
P356
10.1023/A:1008355317514
P478
10 Suppl 1
P577
1999-01-01T00:00:00Z